Author: Liu, Xinsheng; Zhao, Donghong; Zhou, Peng; Zhang, Yongguang; Wang, Yonglu
Title: Evaluation of the Efficacy of a Recombinant Adenovirus Expressing the Spike Protein of Porcine Epidemic Diarrhea Virus in Pigs Document date: 2019_10_8
ID: 1lxd2457_4
Snippet: Currently, adenovirus vector systems derived from human adenoviruses have been widely used in the development of new-generation genetically engineered vaccines [25] [26] [27] . ey show more advantages than other vectors, such as easy construction, high efficiency for gene transfer and propagation, high titers and safety, and strong induction of humoral, mucosal, and cellular immune responses [25] . erefore, the recombinant adenovirus vector vacci.....
Document: Currently, adenovirus vector systems derived from human adenoviruses have been widely used in the development of new-generation genetically engineered vaccines [25] [26] [27] . ey show more advantages than other vectors, such as easy construction, high efficiency for gene transfer and propagation, high titers and safety, and strong induction of humoral, mucosal, and cellular immune responses [25] . erefore, the recombinant adenovirus vector vaccine is a promising approach for the development of new viral vaccines. However, so far, toward a promising vaccine, the study of a recombinant adenovirus vector vaccine for PEDV is underdeveloped. erefore, the development of new PEDV vaccines based on recombinant adenovirus vectors is needed. To achieve this objective, in this study, a novel recombinant adenovirus expressing the PEDV S protein was generated, and its immunogenicity and protective efficacy were evaluated in 4-week-old pigs.
Search related documents:
Co phrase search for related documents- adenovirus vector and high efficiency: 1
- adenovirus vector and high titer: 1, 2, 3, 4
- adenovirus vector and human adenovirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
- adenovirus vector and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- adenovirus vector and PEDV vaccine: 1, 2
- adenovirus vector and PEDV vector vaccine: 1
- adenovirus vector and promising approach: 1, 2
- adenovirus vector and promising vaccine: 1, 2, 3, 4, 5
- adenovirus vector and protective efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adenovirus vector and protective efficacy immunogenicity: 1, 2
- adenovirus vector and recombinant adenovirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- adenovirus vector and recombinant adenovirus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- adenovirus vector and recombinant adenovirus vector vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adenovirus vector and safety high titer: 1
- adenovirus vector and vector system: 1, 2, 3
- adenovirus vector and vector vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63
- adenovirus vector and viral vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- adenovirus vector vaccine and high titer: 1
- adenovirus vector vaccine and human adenovirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Co phrase search for related documents, hyperlinks ordered by date